Search
Oxytetracycline
go.drugbank.com/drugs/DB00595ApprovedInvestigationalVet approvedA tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.
Foretinib
go.drugbank.com/drugs/DB12307InvestigationalForetinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer.
Halofantrine
go.drugbank.com/drugs/DB01218ApprovedWithdrawnIt appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste.
Sevelamer
go.drugbank.com/drugs/DB00658ApprovedInvestigationalIt is marketed by Genzyme under the trade name Renagel.
Fenoldopam
go.drugbank.com/drugs/DB00800ApprovedA dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
Hyaluronidase (ovine)
go.drugbank.com/drugs/DB00070ApprovedHighly purified sheep hyaluronidase for administration by injection into the vitreous of the eye.
Oritavancin
go.drugbank.com/drugs/DB04911ApprovedInvestigationalIt was developed by The Medicines Company (acquired by Novartis). … Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.[L32629]
Streptokinase
go.drugbank.com/drugs/DB00086ApprovedInvestigationalWithdrawnStreptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.
Nifedipine
go.drugbank.com/drugs/DB01115ApprovedInvestigationalNifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine]. … [A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.
Mepolizumab
go.drugbank.com/drugs/DB06612ApprovedInvestigationalThe pathogenesis of eosinophilia is complex, but IL-5 is recognized as a key cytokine involved in the differentiation, recruitment, activation, and prolonged survival of eosinophils in peripheral tissue … Mepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline.